Abstract
Purpose: Patients with HER2-positive metastatic breast cancer (MBC) remain on long-term maintenance anti-HER2 treatment for many years, despite showing radiological complete remission (rCR) or stable disease (rSD). There is currently no consensus regarding discontinuing anti-HER2 treatment in this context, with associated risk of cardiotoxicity, impact on quality of life and cost implications. We present a case series of HER2-positive MBC patients with rCR or rSD who remained off treatment with a durable response and compared outcomes with patients on continuous anti-HER2 treatment for at least 5 years.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call